There have been many books published about the design, conduct and analysis of clinical trials. Why are osteoporosis trials a special case deserving a book of their own? There are three main reasons. Firstly, most diseases have a well-understood definition and etiology. Osteoporosis is a disease that is understood by those working in it, but currently has no definition that is agreeable across the medical and scientific community and a poorly understood etiology. It is within this framework that the pharmaceutical industry is trying to develop new treatments for the so-called “silent epidemic”.
KeywordsBone Mineral Density Fracture Risk Bone Mineral Density Measurement Proven Treatment International Osteoporosis Foundation
Unable to display preview. Download preview PDF.
- 1.Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646–50.Google Scholar
- 2.National Institutes of Health Consensus Development Conference Statement: Osteoporosis Prevention, Diagnosis, and Therapy March 27–29, 2000 ( http://odp.od.nih.gov/consensus/cons/111/111 _statement.pdf).
- 3.Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Report of a WHO Study Group. Geneva: World Health Organization. 1994Google Scholar
- 6.Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland 1964 and revised by the 52nd World Medical Assembly, Edinburgh, 2000. (Available at http://www.wma.net/e/policy/17c_e.html